Surveillance for hepatocellular carcinoma: It is time to move forward
Bo Hyun Kim, Yuri Cho, Joong-Won Park
Clin Mol Hepatol. 2022;28(4):810-813. Published online 2022 Sep 6 DOI: https://doi.org/10.3350/cmh.2022.0257
|
Citations to this article as recorded by
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
Won Sohn, Yong-Han Paik
Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
Shen-Yung Wang
Clinical and Molecular Hepatology.2023; 29(2): 349. CrossRef What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area
Joo Hyun Oh, Jonghyun Lee, Eileen L. Yoon, Soung Won Jeong, Soon Sun Kim, Young Eun Chon, Sang Bong Ahn, Dae Won Jun
Cancers.2023; 16(1): 150. CrossRef
|